168 related articles for article (PubMed ID: 19875645)
1. Targeting the alphavbeta3 integrin for small-animal PET/CT of osteolytic bone metastases.
Wadas TJ; Deng H; Sprague JE; Zheleznyak A; Weilbaecher KN; Anderson CJ
J Nucl Med; 2009 Nov; 50(11):1873-80. PubMed ID: 19875645
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive imaging of osteoclasts in parathyroid hormone-induced osteolysis using a 64Cu-labeled RGD peptide.
Sprague JE; Kitaura H; Zou W; Ye Y; Achilefu S; Weilbaecher KN; Teitelbaum SL; Anderson CJ
J Nucl Med; 2007 Feb; 48(2):311-8. PubMed ID: 17268030
[TBL] [Abstract][Full Text] [Related]
3.
Ocak M; Beaino W; White A; Zeng D; Cai Z; Anderson CJ
Cancer Biother Radiopharm; 2018 Mar; 33(2):74-83. PubMed ID: 29634417
[TBL] [Abstract][Full Text] [Related]
4. HTLV-1 Tax transgenic mice develop spontaneous osteolytic bone metastases prevented by osteoclast inhibition.
Gao L; Deng H; Zhao H; Hirbe A; Harding J; Ratner L; Weilbaecher K
Blood; 2005 Dec; 106(13):4294-302. PubMed ID: 16118323
[TBL] [Abstract][Full Text] [Related]
5. Very late antigen-4 (α(4)β(1) Integrin) targeted PET imaging of multiple myeloma.
Soodgupta D; Hurchla MA; Jiang M; Zheleznyak A; Weilbaecher KN; Anderson CJ; Tomasson MH; Shokeen M
PLoS One; 2013; 8(2):e55841. PubMed ID: 23409060
[TBL] [Abstract][Full Text] [Related]
6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
7. Integrin α(v)β₃ as a PET imaging biomarker for osteoclast number in mouse models of negative and positive osteoclast regulation.
Zheleznyak A; Wadas TJ; Sherman CD; Wilson JM; Kostenuik PJ; Weilbaecher KN; Anderson CJ
Mol Imaging Biol; 2012 Aug; 14(4):500-8. PubMed ID: 21853370
[TBL] [Abstract][Full Text] [Related]
8. Interferon-gamma targets cancer cells and osteoclasts to prevent tumor-associated bone loss and bone metastases.
Xu Z; Hurchla MA; Deng H; Uluçkan O; Bu F; Berdy A; Eagleton MC; Heller EA; Floyd DH; Dirksen WP; Shu S; Tanaka Y; Fernandez SA; Rosol TJ; Weilbaecher KN
J Biol Chem; 2009 Feb; 284(7):4658-66. PubMed ID: 19059914
[TBL] [Abstract][Full Text] [Related]
9. Novel (64)Cu- and (68)Ga-labeled RGD conjugates show improved PET imaging of α(ν)β(3) integrin expression and facile radiosynthesis.
Dumont RA; Deininger F; Haubner R; Maecke HR; Weber WA; Fani M
J Nucl Med; 2011 Aug; 52(8):1276-84. PubMed ID: 21764795
[TBL] [Abstract][Full Text] [Related]
10. Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone.
Virk MS; Petrigliano FA; Liu NQ; Chatziioannou AF; Stout D; Kang CO; Dougall WC; Lieberman JR
Bone; 2009 Jan; 44(1):160-7. PubMed ID: 18929692
[TBL] [Abstract][Full Text] [Related]
11. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
12. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.
Wu Y; Zhang X; Xiong Z; Cheng Z; Fisher DR; Liu S; Gambhir SS; Chen X
J Nucl Med; 2005 Oct; 46(10):1707-18. PubMed ID: 16204722
[TBL] [Abstract][Full Text] [Related]
13. (18)F, (64)Cu, and (68)Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer.
Liu Z; Yan Y; Liu S; Wang F; Chen X
Bioconjug Chem; 2009 May; 20(5):1016-25. PubMed ID: 20540537
[TBL] [Abstract][Full Text] [Related]
14. (64)Cu-labeled CB-TE2A and diamsar-conjugated RGD peptide analogs for targeting angiogenesis: comparison of their biological activity.
Wei L; Ye Y; Wadas TJ; Lewis JS; Welch MJ; Achilefu S; Anderson CJ
Nucl Med Biol; 2009 Apr; 36(3):277-85. PubMed ID: 19324273
[TBL] [Abstract][Full Text] [Related]
15. A cross-species analysis of a mouse model of breast cancer-specific osteolysis and human bone metastases using gene expression profiling.
Sadanandam A; Futakuchi M; Lyssiotis CA; Gibb WJ; Singh RK
BMC Cancer; 2011 Jul; 11():304. PubMed ID: 21774828
[TBL] [Abstract][Full Text] [Related]
16. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression.
Li ZB; Cai W; Cao Q; Chen K; Wu Z; He L; Chen X
J Nucl Med; 2007 Jul; 48(7):1162-71. PubMed ID: 17574975
[TBL] [Abstract][Full Text] [Related]
17. A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model.
Ohno H; Kubo K; Murooka H; Kobayashi Y; Nishitoba T; Shibuya M; Yoneda T; Isoe T
Mol Cancer Ther; 2006 Nov; 5(11):2634-43. PubMed ID: 17121910
[TBL] [Abstract][Full Text] [Related]
18. A comparative study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and (99m)Tc-MDP whole-body bone scanning for imaging osteolytic bone metastases.
Zhang L; Chen L; Xie Q; Zhang Y; Cheng L; Li H; Wang J
BMC Med Imaging; 2015 Mar; 15():7. PubMed ID: 25885599
[TBL] [Abstract][Full Text] [Related]
19. Comparison of two new angiogenesis PET tracers 68Ga-NODAGA-E[c(RGDyK)]2 and (64)Cu-NODAGA-E[c(RGDyK)]2; in vivo imaging studies in human xenograft tumors.
Oxboel J; Brandt-Larsen M; Schjoeth-Eskesen C; Myschetzky R; El-Ali HH; Madsen J; Kjaer A
Nucl Med Biol; 2014 Mar; 41(3):259-67. PubMed ID: 24417983
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
